NatMerkle FT, Ghosh S, Kamitaki N, Mitchell J, Avior Y, Mello C, Kashin S, Mekhoubad S, Ilic D, Charlton M, Saphier G, Handsaker RE, Genovese G, Bar S, Benvenisty N, McCarroll SA & Eggan K (2017)
Human pluripotent stem cells recurrently acquire and expand dominant negative P53 mutations. Nature, 545: 229–233
Joerger AC & Fersht AR (2016)
The p53 Pathway: Origins, Inactivation in Cancer, and Emerging Therapeutic Approaches. Annu Rev Biochem, 85: 375–404
Alexandrova EM, Yallowitz AR, Li D, Xu S, Schulz R, Proia DA, Lozano G, Dobbelstein M, Moll UM (2015)
Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment. Nature, 523: 352–356
Horii T, Yamamoto M, Morita S, Kimura M, Nagao Y, Hatada I (2015)
p53 Suppresses Tetraploid Development in Mice. Sci Rep 5: 8907.
Jiang L, Kon N, Li T, Wang SJ, Su T, Hibshoosh H, Baer R, Gu W (2015)
Ferroptosis as a p53-mediated activity during tumour suppression. Nature 520: 57-62.
Senturk S, Yao Z, Camiolo M, Stiles B, Rathod T, Walsh AM, Nemajerova A, Lazzara MJ, Altorki NK, Krainer A, Moll UM, Lowe SW, Cartegni L, Sordella R (2014)
p53Psi is a transcriptionally inactive p53 isoform able to reprogram cells toward a metastatic-like state. Proc Natl Acad Sci U S A 111: 3287-3296.
Bieging KT, Mello SS, Attardi LD (2014)
Unravelling mechanisms of p53-mediated tumour suppression. Nat Rev Cancer 14: 359-370. 24739573